Perspective Therapeutics (CATX) Receivables - Accured (2022 - 2025)

Perspective Therapeutics' Revenue - Other history runs 6 years deep, the most recent figure standing at $76000.0 for Q1 2026.

• In Q1 2026, Revenue - Other fell 77.78% year-over-year to $76000.0; the TTM figure through Mar 2026 stood at $618000.0 (down 57.99% YoY), while the FY2025 annual figure was $884000.0, down 39.2% from the prior year.
• Revenue - Other came in at $76000.0 for Q1 2026 at Perspective Therapeutics, up from $43000.0 in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $1.0 million in Q4 2025 to a low of $109000.0 in Q4 2022.
• A 3-year average of $670666.7 and a median of $880000.0 in 2024 frame the typical range for Receivables - Accured.
• Across the five-year window, Revenue - Other soared 39.48% in 2024 and plunged 81.62% in 2025, its largest moves.
• Perspective Therapeutics' Revenue - Other stood at $337000.0 in 2023, then slumped by 30.56% to $234000.0 in 2024, then slumped by 81.62% to $43000.0 in 2025, then surged by 76.74% to $76000.0 in 2026.
• According to Business Quant data, Revenue - Other over the past three periods registered $76000.0, $43000.0, and $209000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison